首页> 外文期刊>Journal of Asthma and Allergy >Intranasal ciclesonide for allergic rhinitis
【24h】

Intranasal ciclesonide for allergic rhinitis

机译:鼻内克索奈德治疗过敏性鼻炎

获取原文
       

摘要

Abstract: Ciclesonide is a novel corticosteroid which is optimized for topical use. It is a pro-drug which is activated locally in the airway mucosa, lipid-conjugated for local retention, and has very high protein binding in circulation leading to low systemic bioavailability. These characteristics should lead to highly selective activity with reduced local and systemic side effects. It has been established as an inhaled medication for asthma and has also been shown in double-blind trials to be efficacious for the treatment of seasonal and perennial allergic rhinitis. However no data have yet demonstrated superiority over existing nasal topical corticosteroids, either in terms of efficacy or adverse effects, and trials have not yet clearly shown efficacy in rhinitis in children. Therefore the place of ciclesonide in the treatment of allergic rhinitis relative to other existing products remains unclear.
机译:摘要:西索奈德是一种新型皮质类固醇,已针对局部使用进行了优化。它是一种前药,在气道粘膜中被局部激活,脂质结合以局部保留,并且在循环中具有非常高的蛋白质结合能力,从而导致较低的全身生物利用度。这些特征应导致高度选择性的活性,并减少局部和全身性副作用。它已被确定为可吸入的哮喘药物,并且在双盲试验中也显示出对季节性和常年性变应性鼻炎的治疗有效。然而,无论是在疗效还是在不良反应方面,尚无数据显示优于现有的鼻外用皮质类固醇激素,并且试验尚未明确显示儿童鼻炎的疗效。因此,相对于其他现有产品,在治疗变应性鼻炎中使用ciclesonide的位置仍不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号